Judge: branded companies may be liable for generic versions

Philadelphia Common Pleas judge Mark Bernstein has ruled that branded drug companies may be liable for money spent on the generic version of their drugs when it is marketed for off-label uses.

May 1, 2008

9:04 pm

Philadelphia Common Pleas judge Mark Bernstein has ruled that branded drug companies may be liable for money spent on the generic version of their drugs when it is marketed for off-label uses. He ordered that claims against Warner-Lambert and Pfizer involving a generic version of Neurontin that was produced by a third-party manufacturer and marketed for off-label uses could continue to trial.

From the May 01, 2008 Issue of MM+M - Medical Marketing and Media

From Our Partners

HUB services, patient engagement, and specialty pharmacy: One patient support ecosystem with three core components

Partner Content

HUB services, patient engagement, and specialty pharmacy: One patient support ecosystem with three core components

The evolution of patient needs and rising consumer expectations are shaping a new era in healthcare — one that calls for a paradigm shift in the pharmaceutical industry's approach to patient support.

Omnichannel activation without omniburden

Partner Content

Omnichannel activation without omniburden

Explore solutions for practically implementing omnichannel approaches into your go-to-market activation.

Taking a patient-centric approach to privacy

Partner Content

Taking a patient-centric approach to privacy

This podcast will explore ways to deliver tailored content that activates, educates and empowers patients while prioritizing privacy and consent.

Living brands: How to build brands in the age of omnichannel

Partner Content

Living brands: How to build brands in the age of omnichannel

This podcast looks at how to leverage advancements in data, technology, AI and content development in order to become a Living Brand.